[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX350202B - Combinaciones de agonistas de receptores de muerte 5 (dr5). - Google Patents

Combinaciones de agonistas de receptores de muerte 5 (dr5).

Info

Publication number
MX350202B
MX350202B MX2014011540A MX2014011540A MX350202B MX 350202 B MX350202 B MX 350202B MX 2014011540 A MX2014011540 A MX 2014011540A MX 2014011540 A MX2014011540 A MX 2014011540A MX 350202 B MX350202 B MX 350202B
Authority
MX
Mexico
Prior art keywords
receptor agonist
apoptosis
apoptotic
cancer cells
agonist combinations
Prior art date
Application number
MX2014011540A
Other languages
English (en)
Other versions
MX2014011540A (es
Inventor
Mary Holland Pamela
David Graves Jonathan
Joy Kordich Jennifer
Catherine Piasecki Julia
Nevin Foltz Ian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2014011540A publication Critical patent/MX2014011540A/es
Publication of MX350202B publication Critical patent/MX350202B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición para inducir apoptosis mediada por DR5 de una célula cancerosa en un mamífero, caracterizada porque comprende: a) un primer anticuerpo de unión anti-DR5 que se une específicamente l dominio extracelular del receptor DR5 de la célula cancerosa; y b) por lo menos uno de: i) un segundo anticuerpo de unión anti-DR5 que se une específicamente al dominio extracelular del receptor DR5, en donde el primer anticuerpo y el segundo anticuerpo no se inhiben competitivamente entre sí a partir de la unión específica al receptor DR5, y en donde la unión específica del primer anticuerpo y el segundo anticuerpo inducen de manera cooperativa apoptosis dela célula cancerosa de mamífero sin que requiera linfocitos citolíticos naturales (NK) del mamífero; o ii) un ligando que induce apoptosis relacionada con factor de necrosis tumoral (TRAIL), en donde TRAIL se une específicamente al receptor DR%, y en donde el primer anticuerpo y TRAIL no inhiben competitivamente entre sí de la unión específicamente al receptor DR5, y en donde la unión específica del primer anticuerpo y TRAIL inducen cooperativamente apoptosis de la célula cancerosa de mamífero sin que se requieran linfocitos citolíticos naturales (NK) del mamífero.
MX2014011540A 2012-03-28 2013-03-27 Combinaciones de agonistas de receptores de muerte 5 (dr5). MX350202B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616929P 2012-03-28 2012-03-28
PCT/US2013/034163 WO2013148877A1 (en) 2012-03-28 2013-03-27 Dr5 receptor agonist combinations

Publications (2)

Publication Number Publication Date
MX2014011540A MX2014011540A (es) 2015-03-06
MX350202B true MX350202B (es) 2017-08-30

Family

ID=48087754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011540A MX350202B (es) 2012-03-28 2013-03-27 Combinaciones de agonistas de receptores de muerte 5 (dr5).

Country Status (8)

Country Link
US (2) US20150056204A1 (es)
EP (1) EP2831116A1 (es)
JP (1) JP6219923B2 (es)
AU (1) AU2013239682B2 (es)
CA (1) CA2867631C (es)
HK (1) HK1206760A1 (es)
MX (1) MX350202B (es)
WO (1) WO2013148877A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
EP3048116A1 (en) * 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
SG11201706024YA (en) * 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
EP3337505A4 (en) * 2015-08-19 2019-02-27 Sinotau Pharmaceuticals Group TRAIL-RECEPTOR BINDING AGENTS AND USES THEREOF
AU2016371021B2 (en) 2015-12-17 2020-04-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
EP3672634A1 (en) * 2017-08-24 2020-07-01 Invenra, Inc. Multivalent receptor-clustering agonist antibody constructs
EP4277706A1 (en) * 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DE69312700T2 (de) 1992-04-14 1998-02-19 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1012274T4 (da) 1997-01-28 2011-07-25 Human Genome Sciences Inc Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6100082A (en) 1997-09-23 2000-08-08 Hassanein; Waleed H. Perfusion apparatus and method including chemical compositions for maintaining an organ
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000066156A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1853294A4 (en) 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EP2089425B1 (en) 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds
GB0704651D0 (en) * 2007-03-09 2007-04-18 Ucl Business Plc Composition
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2569336A1 (en) * 2010-05-14 2013-03-20 Amgen Inc. Enhanced death receptor agonists

Also Published As

Publication number Publication date
US20150056204A1 (en) 2015-02-26
HK1206760A1 (en) 2016-01-15
AU2013239682A1 (en) 2014-09-18
CA2867631A1 (en) 2013-10-03
MX2014011540A (es) 2015-03-06
CA2867631C (en) 2019-06-11
US20190284290A1 (en) 2019-09-19
WO2013148877A1 (en) 2013-10-03
JP2015512412A (ja) 2015-04-27
AU2013239682B2 (en) 2016-03-31
EP2831116A1 (en) 2015-02-04
JP6219923B2 (ja) 2017-10-25

Similar Documents

Publication Publication Date Title
MX350202B (es) Combinaciones de agonistas de receptores de muerte 5 (dr5).
PH12017502013A1 (en) Anti-ox40 antibodies and methods of use thereof
PH12016502345A1 (en) Anti-gitr antibodies and methods of use thereof
MX2018006477A (es) Anticuerpos y metodos de uso de estos.
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
EP3702372A3 (en) Anti-cd40 human antibodies
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
TN2015000396A1 (en) Antibody drug conjugates
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
GEP20217271B (en) Combination therapy for the treatment of cancer
CL2013000459A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
IN2014KN00848A (es)
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX370199B (es) Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
PH12014502406A1 (en) Anti-il-23p19 antibodies
MY158499A (en) Anti-dr5 antibodies, polynucleotides and methods
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
IN2014DN09717A (es)
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.

Legal Events

Date Code Title Description
FG Grant or registration